Although patients who have received a kidney transplant have better health than patients on dialysis, heart problems are still the commonest cause of death for kidney transplant recipients. This is because diseases like high blood pressure and diabetes are more common in patients with kidney transplants as well as factors related to having kidney disease itself and the medications transplant recipients have to take to stop them rejecting their transplanted kidney. Exercise is known to help with heart disease in lots of conditions and improves many of the risk factors known to cause heart disease in kidney transplant recipients. This study will investigate whether an individualised, home-based, exercise program improves heart disease in kidney transplant recipients. The study is a randomised controlled trial, with half the patients completing the 12 week exercise programme and the other half continuing with their normal care. The investigators will use detailed MRI scans to assess patient's hearts and blood vessels at the start and end of the study. The investigators will also assess changes in physical function, exercise capacity, blood markers of heart disease, changes in body type and quality of life measures assessed with questionnaires.
Kidney transplantation confers a significant survival advantage over remaining on dialysis, but CVD remains the leading cause of death for RTRs and of graft loss. Acute myocardial infarction accounts for 15-20% of CVD-related deaths in RTRs, but sudden cardiac death, or death from fatal arrhythmia account for at least double this number, suggesting classical atheromatous coronary artery disease driven by traditional cardiometabolic risk factors, is not the dominant driving force of CVD in RTRs. Non-traditional cardiometabolic risk factors including endothelial dysfunction, systemic inflammation, acute rejection, anaemia and deranged bone-mineral metabolism are of at least equal importance in the pathogenesis of CVD in RTRs and drive pathological changes in cardiovascular structure and function that associate strongly with mortality. This is further illustrated by the fact that traditional CVD risk-stratification tools dramatically underestimate cardiovascular risk in patients with CKD, coronary revascularization does not improve outcomes for RTRs as it does in the general population and cardiac events are more likely to be fatal in RTRs than the general population. Immunosuppressive agents are well known to drive traditional CVD risk factors, but also drive non-traditional cardiometabolic risk factors. Cost-effective, deliverable interventions are needed to address the burden of CVD in RTRs by targeting traditional and non-traditional risk factors. Supervised exercise interventions in RTRs improve cardiorespiratory fitness and a variety of traditional and non-traditional risk factors for CVD, including metabolic profile, vascular stiffening, central adiposity and inflammatory cell and cytokine profiles, but are not realistically deliverable in the current financial climate. Home-based exercise training programs have been shown to be deliverable in patients on dialysis and patients undergoing cardiac rehabilitation, but the effectiveness and deliverability of home-based exercise interventions are largely untested in RTRs. It cannot be assumed such programs will be acceptable to RTRs, whose home-lives, social and occupational circumstances are significantly different to dialysis and cardiac patients. Many RTRs have had enforced sedentary lifestyles prior to transplantation as dialysis patients and their goals for rehabilitation as well as the disease processes at work are different to both dialysis and cardiac patients. There are limited data on whether exercise-induced improvements in cardiometabolic risk translate into improvements in cardiovascular structure and function in RTRs. CMR is able to measure multiple clinically pertinent aspects of CVD processes in RTRs that relate closely to outcome with great accuracy, including: * left ventricular hypertrophy * myocardial fibrosis * aortic stiffness * coronary artery function * myocardial steatosis * subclinical systolic and diastolic dysfunction This pilot randomised clinical trial will assess the deliverability of a combined aerobic and resistance, home-based, exercise intervention in RTRs. It will define recruitment and dropout rates from this newly designed, home-based, intervention and baseline values for CMR measures that assess prognostically important aspects of CVD in RTRs for the first time. Furthermore, it will test the effects of the intervention on traditional and novel CMR outcome measures that assess prognostically important aspects of CVD that relate directly to cardiovascular outcomes for the first time, providing estimates of effect-sizes on outcome measures. These data will be used to inform the design of a future, definitive study. This study will further the investigator's ability to make objective measures of cardiovascular health in RTRs, with the opportunity to compare CMR measures with traditional measures of cardiovascular fitness. The qualitative component of this study will refine the exercise intervention to maximize uptake in future studies and adoption into clinical practice.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
50
Patients in the home-based exercise arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
University Hospital Leicester NHS Trust
Leicester, Leicestershire, United Kingdom
Change in Left ventricular mass (g/m)
Measured using multi-parametric cardiac MRI (CMR)
Time frame: Baseline and 12 weeks
Change in left/right ventricular volumes (ml)
Measured using multi-parametric cardiac MRI (CMR)
Time frame: Baseline and 12 weeks
Change in ejection fractions (%)
Measured using multi-parametric cardiac MRI (CMR)
Time frame: Baseline and 12 weeks
Change in native and post-contrast T1 mapping time (ms)
Measured using multi-parametric cardiac MRI (CMR)
Time frame: Baseline and 12 weeks
Change in Myocardial systolic-strain (%)
Measured using multi-parametric cardiac MRI (CMR)
Time frame: Baseline and 12 weeks
Change in peak early-diastolic strain rate (%s-1)
Measured using multi-parametric cardiac MRI (CMR)
Time frame: Baseline and 12 weeks
Change in Aortic pulse wave velocity (m/s)
Measured using multi-parametric cardiac MRI (CMR)
Time frame: Baseline and 12 weeks
Change in aortic distensibility (mmHg-1×10-3)
Measured using multi-parametric cardiac MRI (CMR)
Time frame: Baseline and 12 weeks
Change in Myocardial and hepatic triglyceride content (%)
Measured using multi-parametric cardiac MRI (CMR)
Time frame: Baseline and 12 weeks
Recruitment Rate
The feasibility of recruitment and interest of patients is an essential component of whether a full trial is feasible. The number of eligible patients and number of consented will be recorded. Monthly recruitment rate and the time taken to recruit 10 (25%), 20 (50%), 30 (75%), and 40 (100%) patients will be recorded.
Time frame: Post 12 week intervention
Number of participants lost to follow up
This is the number of participants leaving the trial due to being uncontactable
Time frame: Post 12 week intervention
Number of exercise sessions completed per week
This will assess adherence to the intervention
Time frame: Post 12 week intervention
Number of participants dropping out of the trial
Otherwise known as the attrition rate
Time frame: Post 12 week intervention
Number of adverse events
This is a measure of the trial safety
Time frame: Post 12 week intervention
Aerobic Capacity (change)
Measured by cardiopulmonary exercise test which produces V02 (maximal oxygen uptake) in both l/min and ml/kg/min. This is a measure of a participants aerobic capacity.
Time frame: Baseline, 2 weeks, 4 weeks and 12 weeks
Timed up and go test (TUAG)(change)
To determine fall risk and measure the progress of balance, sit to stand and walking. Patient sits and then the time taken to stand up and walk 3 meters and return is measured. If a patient took 14 seconds or longer he or she was classified as high-risk for falling
Time frame: Baseline and 12 weeks
Habitual Physical Activity (change)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Via accelerometry
Time frame: Baseline and 12 weeks
Lower limb strength (change)
Dynamometry
Time frame: Baseline and 12 weeks
Upper Limb Strength (change)
Hand grip
Time frame: Baseline and 12 weeks
Change in circulation markers of systemic inflammation
Blood Sampling including but not limited to IL-6, CRP, IL-10, TNF-Alpha
Time frame: Baseline and 12 weeks
Muscle quality using Ultrasound Imaging (change)
Cross-sectional area (cm2)
Time frame: Baseline and 12 weeks
Muscle quality using Ultrasound Imaging (change)
fat thickness (mm)
Time frame: Baseline and 12 weeks
Muscle Elasticity (change)
Muscle elasticity will be measures using a MyotonPro device
Time frame: Baseline and 12 weeks
Lower limb endurance (change)
Sit to stand 60 test measuring how many 'sit to stands' can be performed in 60 seconds
Time frame: Baseline and 12 weeks
Balance (change)
Measured using a 'wii-fit' style board. Better balance is an idicator of falls risk
Time frame: Baseline and 12 weeks
Gait speed (change)
Gait speed is measure as the time taken to walk 4 meters. Slower speeds have been linked to higher mortality risk
Time frame: Baseline and 12 weeks
Height
Height measured in meters
Time frame: Baseline
Weight (change)
Weight measured in kg
Time frame: Baseline and 12 weeks
Body fat % (change)
Body fat measured using bio electrical impedance analysis
Time frame: Baseline and 12 weeks